

XII ANNUAL Ri.MED SCIENTIFIC SYMPOSIUM

Cancer Immunotherapy

Recent progress and future challenges

FRIDAY
OCTOBER
12th 2018

Palazzo dei Normanni
Sala Piersanti Mattarella
Piazza del Parlamento
Palermo - Italy

8.30 am SYMPOSIUM REGISTRATION

9.00 am **Introduction and Ri.MED Overview**

Dario A. A. Vignali, Ph.D. - *Scientific Director, Fondazione Ri.MED*
Alessandro Padova, Ph.D. - *Director General, Fondazione Ri.MED*
Angelo Luca, M.D. - *Director, IRCSS ISMETT*

SESSION I

9.30 am **The Tumor Immune Microenvironment: Inhibitory Mechanisms and Therapeutic Opportunities**

Keynote speaker: Dario A. A. Vignali, Ph.D.

10.15 am **Using Genomics to understand T Cell Dynamics in the Tumor Microenvironment**
Ana C. Anderson, Ph.D.

10.45 am COFFEE BREAK

SESSION II

11.05 am **Targeting Regulatory T Cells for Therapeutic Gain: Means and Mechanisms**
Sergio A. Quezada, Ph.D.

11.35 am **Unwinding CD137 and Interleukin-8 in Cancer Immunotherapy**
Ignacio Melero, M.D., Ph.D.

12.05 am **Targeting the differential Function of Tumor infiltrating B Cells in solid Tumors to increase Immunotherapeutic Efficacy for Cancer Patients**
Tullia Bruno, Ph.D.

12.35 pm LUNCH

SESSION III

1.15 pm **Lesson from Cancer: "Flipping" over Monocytes into Immune-suppressive Cells**
Vincenzo Bronte, M.D., Ph.D.

1.45 pm **TILs to TCRs: Adoptive T Cell Therapy Strategies for Poorly Immunogenic Cancers**
Udai S. Kammula, M.D., FACS

2.15 pm COFFEE BREAK

SESSION IV

2.35 pm **Novel I-O Combination: the Role of Anti-LAG-3 and Adenosine Pathway Inhibitors**
Paolo Ascierto, M.D.

3.05 pm **Development and Integration of Immunotherapy into the Management of Head and Neck Cancer: Dangers and Opportunities**
Keynote speaker: Robert L. Ferris, M.D., Ph.D.

3.50 pm CLOSING REMARKS

KEYNOTE SPEAKERS:

Dario A. A. Vignali, Ph.D.

Scientific Director, Fondazione Ri.MED
The Frank Dixon Chair in Cancer Immunology,
Vice Chair and Professor of Immunology, Department of Immunology,
University of Pittsburgh School of Medicine, and Co-Leader, Cancer
Immunology and Immunotherapy Program,
Co-Director, Tumor Microenvironment Center, UPMC Hillman Cancer Center,
Pittsburgh, USA

Robert L. Ferris, M.D., Ph.D.

Director, UPMC Hillman Cancer Center
Hillman Professor of Oncology
Associate Vice-Chancellor for Cancer Research
Co-Director, Tumor Microenvironment Center
Professor of Otolaryngology, of Immunology, and of Radiation Oncology,
Pittsburgh, USA

SPEAKERS:

Ana C. Anderson, Ph.D.

Associate Professor of Neurology, Broad Institute, Harvard Medical School
and Brigham and Women's Hospital, Boston, USA

Paolo Ascierto, M.D.

Director, Unit of Melanoma, Cancer Immunotherapy and Innovative Therapy,
National Tumor Institute Fondazione "G. Pascale", Naples, Italy

Vincenzo Bronte, M.D., Ph.D.

Professor, Department of Medicine, Verona University Hospital, Verona, Italy

Tullia Bruno, Ph.D.

Research Assistant Professor Department of Immunology University of
Pittsburgh, Pittsburgh, USA

Ignacio Melero, M.D., Ph.D.

Co-Director, Immunology and Immunotherapy Service
Senior Researcher, Clinica Universidad de Navarra
Senior Investigator, Centro de investigación Médica Aplicada (CIMA),
Pamplona, Spain

Sergio Quezada, Ph.D.

Group Leader, Immune Regulation and Tumor Immunotherapy Lab
University College London Cancer Institute, London, UK

Udai S. Kammula, M.D., FACS

Director, Solid Tumor Cell Therapy Program, UPMC Hillman Cancer Center,
Pittsburgh, USA

CHAIRMAN: Dario A. A. Vignali, Ph.D.